News
AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U ...
22h
Zacks.com on MSNJ&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.
4d
Wirral Globe on MSNWirral woman dismissed by doctors diagnosed with cancerA WIRRAL woman was diagnosed with incurable stage 4 breast cancer after her tumour was dismissed as her having "lumpy boobs" for ...
Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and increasingly capital-constrained environment.
Kisqali was approved for the new indication on the back of the NATALEE trial, in which adding Kisqali to standard treatment ...
Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.
A study published by Caris showed that certain tumor types had very low or no HER2 overexpression, which has implications for biomarker testing strategies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results